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A biochemical activity, that is, enzymatic reaction or molecular interaction, frequently
involves a molecule, for example, an enzyme, capable of interacting with numerous sub-
strates or partners. Speciﬁcity is a fundamental property of biochemical activities, and
relative speciﬁcity refers to the situation whereby a molecule interacts with multiple sub-
strates or partners but with different afﬁnities. Here, a hypothesis is proposed that any
molecule, such as an enzyme, would have a range of preferences or relative speciﬁcity
for its many native substrates, which differentially impacts the phenotypes of these sub-
strates and hence shapes the relevant biological processes in vivo.While the mechanisms
underlying the speciﬁc recognition between enzymes and individual substrates have been
studied extensively, whether any enzyme exhibits intrinsic selectivity toward its ensemble
of substrates is often overlooked, and whether this selectivity has any functional conse-
quences is much less appreciated. There are, however, several lines of evidence in the
literature that are consistent with the hypothesis and reviewed here. Furthermore, this
hypothesis is supported by our analyses of a number of diverse biochemical systems at
a large scale. Thus, the human microRNA processing machinery possesses relative speci-
ﬁcity toward its hundreds of substrates, which might contribute to differential microRNA
biogenesis; the promoter binding afﬁnity of the transcription factor Ndt80 might regulate
Ndt80 target mRNA expression in the budding yeast; Cdk1 kinase speciﬁcity might lead to
variable substrate phosphorylation in vivo; and the density of HuR deposition to its thou-
sands of RNA targets might partly explain differential RNA expression in human cells. It is
proposed, therefore, that relative speciﬁcity is a universal property of complex biochemical
systems and that the hypothesis could denote a general principle in biology.
Keywords: biochemical activity, relative specificity, substrate selectivity, regulatory function
INTRODUCTION
Speciﬁcity in biochemical activities has two components, absolute
speciﬁcity and relative speciﬁcity. For absolute speciﬁcity, a mol-
ecule, symbolized as E here, recognizes a group of substrates
or interacting partners (symbolized as {S}) but not any oth-
ers. For relative speciﬁcity, an E interacts with more than one
cognate {S} differentially. The functional implication of absolute
speciﬁcity is self-evident, so the focus here is on relative speci-
ﬁcity, although absolute speciﬁcity can be viewed as an extreme
case of relative speciﬁcity. This paper addresses a hypothesis that
an E has a range of afﬁnities or preferences for its many {S},
and that such selectivity differentially impacts the {S} to inﬂu-
ence the underlying biological processes at a large scale in vivo
(Figure 1A). Below, I will ﬁrst explain the hypothesis in more
detail. While the proposition appears intuitively plausible, it is
actually understudied and not grounded in real data in most bio-
chemical systems. Next, potential evidence in the literature will
be summarized. Our own work will then be presented to further
support the hypothesis and to demonstrate strategies to test the
hypothesis directly. Lastly, the implications of the hypothesis will
be discussed.
RELATIVE SUBSTRATE PREFERENCES ARE NOT WELL
UNDERSTOOD AT THE SYSTEMS LEVEL
The number of {S} varies greatly with E. For example, hemoglo-
bin binds a handful of {S}, e.g., O2, CO2, CO, with CO having a
higher afﬁnity than O2 for hemoglobin, leading to a textbook con-
sequence. On the other hand, the ribosome and RNA polymerase
II have tens of thousands of {S} in multicellular organisms. In the
middle of the spectrum, an enzyme may catalyze the conversion of
dozens or hundreds of substrates, and amoleculemay interactwith
a large number of partners; some examples are protein kinases,
transcription factors, and microRNAs (miRNAs). The hypothesis
of interest is broadly applicable but was conceived with complex
systems in mind wherein an E has at least dozens or hundreds of
cognate {S}. The signiﬁcance of speciﬁc recognition sequences in
individual or model targets has been extensively investigated for E
such as kinases and transcription factors, but whether an E pos-
sesses selectivity toward its ensemble of {S} is often unknown, and
whether this selectivity has any in vivo relevance is seldom reported
in the literature. For example, protein kinases and transcription
factors typically recognize degenerate sequences in hundreds of
native {S}, so it is plausible yet hardly reported that, based on
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FIGURE 1 | Schematics of how an E interacts with {S}, represented by
S1, S2, and S3.The interactions yield the respective products P1, P2, and
P3, with the remaining S1, S2, and S3. The letter size symbolizes the
abundance of S and P, with the starting S1–S3 being equal for simplicity. (A)
E discriminates amongst S to yield different amounts of P1, P2, and P3, as
the central hypothesis predicts. (B) E interacts with S1–S3 identically, a
commonly assumed situation. Because S and P likely have different
activities in vivo, (A) and (B) will lead to different functional outcomes
downstream.
their sequences, some {S} would be better phosphorylated or tran-
scribed than others in vivo. Additionally, do the core transcription
machinery and the core translation machinery possess any innate
preferences toward their tens of thousands of targets genes and
mRNAs, respectively, and do the preferences contribute to differ-
ential gene expression in vivo? Components of these machineries
might have isoforms and be differentially expressed, which is reg-
ulatory in nature (Goodrich and Tjian, 2010; Kondrashov et al.,
2011). Thehypothesis formulatedhere,however,differs fromother
theories by projecting that regulation can originate at the most
basic level from the biased interactions between a single E and its
vast number of {S}.
There is a dearth of studies that explicitly address the above or
analogous questions, for two reasons. The ﬁrst is that the potential,
regulatory role of E:{S} selectivity is often overlooked. By default,
an E is frequently portrayed to operate passively or constitutively,
doing an assembly line-like task on its entire set of {S}, regulated
only from outside of the system (Figure 1B). The second reason
is that it is difﬁcult to study the phenomena in complex systems.
Firstly, we usually do not know all or most of the genuine {S}
for any E. Secondly, {S} or the products in vivo must be quan-
tiﬁed at a large scale, but the essential genomics or proteomics
tools were not available until the late 1990s. Thirdly, a representa-
tive assay might not exist to characterize biochemical interactions
in vitro. For example,only a few artiﬁcial or authentic {S} have been
tested using the in vitro transcription or translation systems, and
the products usually do not phenocopy full-length pre-mRNAs
or proteins typical in vivo. As a result, there are few reports of
E discriminating amongst its large set of {S}. Lastly, one has to
isolate the effect of E on {S}, as {S} are invariably controlled by
multiple factors besides E in vivo. Thus, even if an E’s relative
speciﬁcity toward a small number of {S} in vitro correlates with
the phenotypes of {S} in vivo, it remains possible that the cor-
relation results from the fortuitous action of factors other than
the E.
POTENTIAL SUPPORTING EVIDENCE IN THE LITERATURE
Despite the challenges, there is evidence in the literature that
might support the hypothesis in complex biochemical systems.
An example is eIF4E, which binds the 5′ m7GpppN cap of
mRNAs to initiate mRNA scanning and translation (Sonenberg,
2008). All capped mRNAs are eIF4E substrates, but eIF4E over-
expression preferentially stimulates the translation of a subset
of mRNAs that promote tumorigenesis in mammalian systems.
These mRNAs often have a long and stable 5′ untranslated region
that presumably requires elevated eIF4E activity, although the
direct mRNA selectivity of eIF4E has not been extensively exam-
ined in vitro. A transcript-speciﬁc role has also been ascribed
to ribosomal proteins (Kondrashov et al., 2011; Topisirovic and
Sonenberg, 2011). Deﬁciency in ribosomal protein L28 reduces
the translation of a subset of Hox mRNAs in mouse embryos,
which is not observed in mutants of several other ribosomal
proteins (Kondrashov et al., 2011). Likewise, mutations of gen-
eral transcription factors differentially impact the expression of
distinct sets of genes (Holstege et al., 1998). The origin of the
selectivity of L28 or general transcription factors, however, is
unknown.
Another example is ligand–receptor interaction. Distinct ago-
nists ({S}) can differentially impact downstream signaling path-
ways even when bound to the same receptor (E), e.g., the μ-
opioid receptor, β2-adrenergic receptor, vasopressin, serotonin,
and dopamine receptors (reviewed in Urban et al., 2007). The
concepts of intrinsic efﬁcacy, functional selectivity, or agonist-
selectivity signaling have been proposed to explain this phenom-
enon (Urban et al., 2007). How E discriminates amongst {S}
is not well characterized, but it likely necessitates E to adopt
multiple active conformations upon binding by different {S}.
Even less understood is how these conformations could differ-
entially activate downstream signaling molecules, quantitatively
or qualitatively. An analogous mechanism may partially explain
the multifunctionality or promiscuity of other proteins, e.g., the
cytochrome P450 enzymes (Khersonsky and Tawﬁk, 2010; Atkins
andQian,2011). The general explanation is that a protein (E) exists
in a multiplicity of conformations due to inherent structural plas-
ticity. {S} may bind it with different afﬁnities at overlapping but
non-identical sites to form complexes with different conforma-
tions, and the {S} reactive groups may position in the complexes
differently, thereby affecting the subsequent catalysis or product
release. Nevertheless, inmost cases we probably do not even realize
the full spectrum of substrates for such E, and a single molecule
can be the substrates of several enzymes in a cell or tissue speciﬁc
manner, which hampers the global analysis of relative speciﬁcity
in vitro and in vivo.
The most revealing case is perhaps the HuR protein, which sta-
bilizes RNAs by binding preferentially to short uridine stretches.
Lebedeva et al. (2011) and Mukherjee et al. (2011) identiﬁed HuR
substrates at the global scale and showed that HuR has thousands
of RNA targets with variable, potential HuR binding sites and HuR
association in cells, and that the degree of HuR binding correlates
with HuR-dependent stability of the target RNAs.
While these studies reported that E:{S} interactions can lead to
distinct effects depending on {S}, the phenomena have not been
generalized, and the detailed mechanism is unavailable with the
exception of HuR (but see below). This is largely due to the lack
of suitable in vitro biochemical assays or detailed, structural data,
leaving open alternative explanations.
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REGULATION OF miRNA EXPRESSION BY THE GENERAL
miRNA PROCESSING MACHINERY
The rationale behind our hypothesis is that relative speciﬁcity is
likely a universal, direct, and natural consequence when an E has
to interact with many native {S} with different sequences or struc-
tures in any complex system, and that in vivo phenotypes can
partly be explained by the relative speciﬁcity of the underlying bio-
chemical activities. Our own work has aimed to directly test this
hypothesis. First we studied the biogenesis of miRNAs. miRNAs
are a class of∼22-nucleotide-long RNAs, in mammals encoded by
hundreds of known miRNA genes (Ambros, 2004; Newman and
Hammond, 2010). A canonical miRNA is initially transcribed as
part of a long primary transcript. An RNase called Drosha cleaves
this transcript to liberate a hairpin precursor of ∼60 nucleotides.
Dicer, another RNase, cleaves the precursor to produce an ∼22
basepair RNA duplex intermediate. Subsequently, an Argonaute
(Ago) protein binds to the duplex and selects the mature, single-
stranded miRNA. The Ago:miRNA complex then functions by
repressing target gene expression downstream.
We investigated the cleavage of hundreds of human primary
miRNA substrates by Drosha in vitro (Feng et al., 2011). Drosha
(E) cleaves these RNAs ({S}) with different efﬁciencies, which
positively correlates with the relative expression levels of the cor-
responding mature miRNAs in vivo, and the speciﬁcity could
be partially explained by different structural properties of the
substrates. Considering the well-known biochemical function of
Drosha, we suggested that Drosha selectivity determines, to a sig-
niﬁcant extent, whether a transcript encodes a miRNA or not, and
how efﬁciently a miRNA is produced in vivo (Feng et al., 2011).
In a related study, we showed that stable Ago2 overexpres-
sion increases or decreases the maturation of distinct miRNAs in
human cells (Zhang et al., 2009). This result is analogous to that of
eIF4E. Because Ago2:miRNA complexes inhibit the expression of
target mRNAs, the differential effects of Ago2 might be accounted
for by the interdependence of the expression of speciﬁc mRNAs
and miRNAs (Zhang et al., 2009).
SELECTIVITY IN Ndt80 AND Cdk1 FUNCTIONS
Our Drosha study combined in vitro assays and in vivo data analy-
sis to explicitly test the hypothesis. No other biological systems,
however, have been examined in a similar and deliberate man-
ner. The best functional genomics studies have been performed in
S. cerevisiae, so I carried out literature search, data mining, and
analysis for this model organism.
Ndt80 is a transcription factor involved in middle gene induc-
tion (∼5 h) during sporulation (Chu and Herskowitz, 1998). Jolly
et al. (2005) showed that Ndt80 binds DNA with nucleotide pref-
erences in an in vitro binding assay, generated a corresponding,
position weight matrix (PWM), and then curated a list of 145
known and predicted Ndt80 target genes. For this analysis, the
potential Ndt80 binding sites in these 145 genes were retrieved
using the YEASTRACT database (Teixeira et al., 2006), and their
PWM scores calculated (Table A1 in Appendix). If a gene has
more than one potential Ndt80 site, the highest PWM score was
used as the representative. Not surprisingly, the target genes have
variable PMWscores (TableA1 inAppendix), soNdt80 could asso-
ciate with the promoters with different afﬁnities or probabilities,
suggestive of relative speciﬁcity in vivo. Next, mRNA expression
datawere extracted fromChu et al. (1998)where yeast gene expres-
sion from 0 to 11.5 h after the initiation of sporulation was deter-
mined by microarray analyses (Table A1 in Appendix). The PWM
scores were then correlated with target mRNA expression at the
different time points (SPSS, IBM). At 0 h, the Spearman rank cor-
relation coefﬁcient ρ= 0.008, p value= 0.93; at 0.5 h, ρ=−0.013,
p = 0.88; at 2 h, ρ= 0.077, p = 0.36; at 5 h, ρ= 0.35, p = 0.00002;
at 7 h, ρ= 0.30, p = 0.0003; at 9 h ρ= 0.31, p = 0.0002; at 11.5 h,
ρ= 0.29, p = 0.0004. The positive correlation peaks at 5 h, con-
sistent with the known function of Ndt80 (Chu and Herskowitz,
1998). This result suggested that Ndt80 binding speciﬁcity, deter-
mined in vitro, could translate to differential target gene expression
in vivo.
The other example is protein phosphorylation by S. cerevisiae
Cdc28, or Cdk1, which controls cell cycle progression. Ubersax
et al. (2003) showed that the mitotic Cdk1 phosphorylates hun-
dreds of proteins in vitro. The extent of substrate phosphorylation,
or P-scores, ranged over seven orders of magnitude, which can-
not be explained by the differences in possible phosphorylation
sites. Cdk1, therefore, discriminates amongst {S} in vitro, just like
Drosha.
Does this speciﬁcity impact the phosphorylation levels of Cdk1
substrates in vivo? Using mass spectrometry, Holt et al. (2009)
identiﬁed phosphorylation sites in hundreds of Cdk1 substrates
in especially cells arrested by the overexpression of a stable mitotic
cyclin. For this analysis the Signal/Noise (S/N) ratio was used
as a proxy for phosphorylation in vivo, although data from Holt
et al. (2009) did not allow for normalization against total protein
expression. For a protein with more than one phosphopeptide, the
sum of all the S/N ratios was used to represent its phosphorylation
(Table A2 in Appendix). P-scores correlated positively and sig-
niﬁcantly with S/N ratios: n = 144, ρ= 0.29, p = 0.0005, so Cdk1
speciﬁcity in vitro (Ubersax et al., 2003) might partially explain
differential substrate phosphorylation in vivo (Holt et al., 2009).
The analyses of Ndt80 and Cdk1 functions demonstrated for
the ﬁrst time a global correlation between the in vitro speciﬁcity
and in vivo functions of a transcription factor and a protein
kinase, respectively. Does the relative speciﬁcity have a physio-
logical impact? Differential miRNA and mRNA expression is pre-
sumably regulatory and functionally relevant in vivo. And because
a phosphoprotein and its non-phosphorylated counterpart often
differ in their activity, subcellular localization, and/or stability,
Cdk1 might phosphorylate its many substrates to various degrees
to regulate cell cycle progression. This is a novel angle to look at
Cdk1 functions that merits further investigations.
HuR BINDING AND TARGET RNA EXPRESSION
Lebedeva et al. (2011) and Mukherjee et al. (2011) convincingly
demonstrated that the degree of HuR association predicts HuR-
dependent RNA stabilization. The authorsmeasuredHuR associa-
tion by RNA sequencing or arrays following HuR immunoprecip-
itation from cell cultures, and HuR-dependent RNA stabilization
by the HuR knockdown strategy. A prediction from our hypoth-
esis, not explicitly tested in these studies, is that HuR speciﬁcity
positively contributes to the absolute expression levels of target
RNAs.
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HuR consensus RNA binding sequences are very degenerate
and not precisely deﬁned (Levine et al., 1993; de Silanes et al.,
2004; Meisner et al., 2004; Ray et al., 2009), so a PWM score
might not adequately depict a potential HuR:target interaction.
Furthermore, both Lebedeva et al. (2011) and Mukherjee et al.
(2011) showed that RNAs ({S}) can vary substantially in their
numbers of HuR binding sites, a sign of HuR relative speciﬁcity.
Consequently, the number of HuR binding sites or its varia-
tions were used here to represent HuR:RNA association, and
the data of Lebedeva et al. (2011) and Mukherjee et al. (2011)
re-analyzed. The strongest correlation was detected between the
fragments/read pairs per kilobase of exon per million read pairs,
reﬂecting relative mRNA expression, and the fraction of length
covered by binding clusters, reﬂecting HuR association normal-
ized against transcript size (Table S2 in Lebedeva et al., 2011).
For the 4,845 consensus HuR targets, the Spearman rank correla-
tion coefﬁcient is 0.39,p = 2.6× 10−171; for the 1,216 conservative
targets, the coefﬁcient is 0.36, p = 2.8× 10−38 (Table S2 in Lebe-
deva et al., 2011). Using the predicted or veriﬁed HuR binding
site numbers without transcript size normalization yielded pos-
itive but less signiﬁcant correlations to the RNA sequencing or
array data (Lebedeva et al., 2011; Mukherjee et al., 2011; data
not shown). This new result suggested that the density of HuR
deposition best explains the differential expression of HuR target
RNAs.
INTERPRETATIONS OF OUR RESULTS
Our studies serve as examples to illustrate how one can test the
hypothesis directly. As the ﬁrst step, one needs to realize that rel-
ative speciﬁcity is a general and functioning characteristic in any
complex systems. In step 2, a biochemical assay, usually with puri-
ﬁed components in vitro, will examine the interactions between
an E and {S} at a large scale. In step 3, a global approach will
characterize {S} or the products in cells or in vivo. As the last step,
a signiﬁcant statistics correlation is expected between the results
from steps 2 and 3. In our work, because the biochemical activ-
ities of Drosha, Ndt80, Cdk1, and HuR are ﬁrmly established,
the observed correlations present strong evidence that the relative
biochemical speciﬁcity is causal and functional in vivo.
Somewhat remarkably, our conclusions were reached despite
the complexities in the underlying biological problems and data
acquisition. For example, Drosha cleavage efﬁciencies can only be
approximated (Feng et al., 2011), S/N ratio depends on phospho-
rylation efﬁciency, peptide extraction or ionization, and protein
expression, and PWM gives mere estimates. Concentrations of {S}
in vivo might deviate greatly from Km, and {S} will compete for
the access to E, which might skew or complicate the effects of E
selectivity. Multiple steps and factors inﬂuence miRNA matura-
tion,mRNA expression, or protein phosphorylation. Our analyses
assumed that the speciﬁcity of Ewas sufﬁciently independent of all
the other contributing factors, such that examining a large num-
ber of {S} would enable us to assess statistical signiﬁcance in the
complex processes. No strategy, however, can completely ﬁlter out
the effects by every interfering factor in vivo.
With these considerations, it is not surprising that relatively
small correlation coefﬁcients were obtained. There are two angles
to look at the numbers. One is that they reﬂect spurious correla-
tions. Nevertheless, the coefﬁcients are similar to many reported
in the literature (e.g., Lackner et al., 2007; Tuller et al., 2010), the
correlations are signiﬁcant in diverse systems, and they can all be
explained biochemically. Alternatively, they suggest that the rela-
tive E:{S} speciﬁcity is only one of myriad factors that contribute to
the ﬁnal phenotype in vivo, but it still plays an integral and impor-
tant role. For example, protein degradation does not contribute
to global protein expression as signiﬁcantly as other factors, but
it is arguably still an important regulatory mechanism (Schwan-
häusser et al., 2011). Furthermore, for the reasons given above,
these coefﬁcients likely underestimate the relationships in vivo,
and more inclusive and precise measurements and better analytic
tools in the future may improve the values and elucidate the true
signiﬁcance of E:{S} speciﬁcity.
IMPLICATIONS AND CONCLUDING REMARKS
How biological processes are regulated is a subject of intense
investigations yet remains incompletely understood, especially at
the systems level. This hypothesis posits that relative speciﬁcity
is the rule rather than the exception at a global scale such that
we must pay more attention to the functional role of substrate
preferences in individual biochemical activities. Take a familiar
example, to comprehend how genes A, B, C, etc are differen-
tially transcribed, a standard work plan is to identify the relevant
chromatin modiﬁers, speciﬁc transcription factors, and RNA-
processing complexes. The knowledge is incomplete, however,
until we understand their relative afﬁnities or efﬁcacies for the
speciﬁc genes, elucidate the non-identical impact from RNA poly-
merase II and the general transcription factors, and quantify their
individual contributions.
That biochemical activities regulate biological processes is a
truism, and as stated by Mukherjee et al. (2011), “All targets were
not quantitatively equivalent.” This hypothesis, however, expli-
cates how a certain level of regulation is achieved and brings
attention to the regulatory properties of many entities that have
been traditionally ignored or greatly underappreciated. Testing the
hypothesis for the functions of Drosha, Ndt80, Cdk1, and HuR
sheds light on how diverse systems are regulated in vivo. In addi-
tion, studying global relative speciﬁcity has provided new insights
into its biological signiﬁcance. For example, eIF4E selectivityman-
ifests itself in promoting tumorigenesis, agonist-selective signaling
may explain, in part, how, e.g., different opioid drugs elicit differ-
ent physiological responses, and Drosha processing may control
the speciﬁcity and efﬁciency of miRNA biogenesis.
To conclude, this paper emphasizes the pervasive, functional
role of relative speciﬁcity in biochemical activities and outlines
a general strategy to analyze its signiﬁcance in complex systems.
Future studies to test the hypothesis will advance our knowledge of
how biological processes are regulated and how relative speciﬁcity
has evolved.
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APPENDIX
Table A1 |Transcription regulation by Ndt80.
ORF Position PWM score t0 t0.5 t2 t5 t7 t9 t11.5
YDR438W −180 1.13 0.713 1.875 0.883 3.251 8.539 4.887 4.212
YFL011W −820 0.23359752 0.738 0.18 0.775 3.394 17.14 12.53 28.01
YFR032C −130 1.13 0.725 0.604 0.657 12.1 20.47 14.35 6.006
YHR185C −150 0.579012 0.79 0.571 0.919 7.92 15.91 11.5 6.221
YDL186w −160 1 0.907 0.537 1.082 3.581 9.737 6.778 5.989
YDR065w −110 1.17 0.638 0.572 0.94 3.415 8.346 7.332 5.056
YER085c −90 1 0.704 0.761 0.8 3.424 10.02 8.983 5.976
YDL114w −350 0.7137 0.723 0.567 0.732 3.305 10.78 7.282 9.857
YOL015W −110 0.5162 0.538 0.375 0.551 7.373 30.36 19.75 20.38
YDR371W −80 0.9492 0.844 1.269 0.979 3.934 14.14 15.64 20.54
YDR042C −220 1.17 0.992 0.683 0.945 3.778 11.99 9.581 12.34
YGR273C −410 0.725172 1.04 0.514 0.764 5.664 31.41 20.3 38.05
YOL024W −100 0.7137 0.886 0.633 1.006 5.206 15.19 9.306 17.22
YDR218C −90 1.17 0.741 0.857 1.013 12.06 38.72 22.89 60.56
YJL037W −270 1.17 1.07 0.76 0.98 9.168 22.85 14.6 40.65
YNL033W −200 0.599508 0.854 0.92 1.027 4.484 14.28 6.958 19.46
YDR317W −150 1.17 0.873 0.869 0.663 6.788 16.3 13.39 21.43
YLR343W −150 0.6903 0.84 0.883 0.733 8.492 24.39 16.58 41.74
YNL318C −120 0.6903 0.697 0.683 0.731 8.678 25.47 22.36 36.15
YMR017W −340 0.8424 0.816 0.877 0.838 5.582 19.65 15.07 32.55
YNL019C −200 0.599508 0.673 0.878 0.933 5.235 16.58 10.11 15.68
YLR308W −160 1 0.861 1.164 0.863 13.83 25.89 17.35 38.45
YDR260C −900 0.724104 1.009 1.081 1.075 3.207 9.433 4.805 5.78
YML119W −160 0.9828 0.928 0.886 1.071 4.886 15.09 9.413 6.545
YLR307W −120 0.9828 0.771 0.853 1.151 9.16 19.16 14.61 11.32
YPR027C −250 0.9492 0.811 0.793 0.918 4.635 8.003 6.307 7.148
YEL023c −520 0.6667 0.755 0.574 1.193 17.78 34.12 8.509 62.09
YFR023W −230 1.17 0.691 0.575 0.78 17.33 21.26 25.76 54.45
YPL130W −160 1.13 0.53 0.496 0.895 12.5 20.65 11.66 28
YOR313C −200 1.13 0.811 0.848 1.085 32.76 20.3 15.71 47.71
YER106w −156 1.17 0.739 0.451 0.79 9.869 14.58 14.64 5.726
YOR298W −120 1.17 0.525 0.316 1.066 3.15 10.07 7.816 4.526
YAL018C −180 1 0.718 0.582 0.592 13.22 25.2 10.17 21.86
YBR250W −185 1.17 0.895 0.699 0.963 7.33 9.702 3.808 6.169
YJR119C −190 0.8424 0.759 0.669 0.887 3.024 9.484 7.906 5.538
YGL116W −86 1.17 0.884 1.424 1.166 5.669 27.1 14.72 22.09
YJL160C −210 1 0.84 1.229 1.036 5.184 17.08 10.97 26.36
YOL047C −120 1.13 1.029 1.198 0.922 6.203 13.87 7.925 13.85
YFL012W −160 1.17 0.835 1.069 1.032 3.316 5.406 6.096 6.138
YOR365C −130 0.97 0.719 0.893 0.839 4.296 9.187 10.38 13.87
YGL170C −120 1.17 0.761 0.461 0.902 12.08 28.59 20.9 44.8
YHR184W −90 1.17 0.836 0.48 0.828 23.33 42.59 28.61 46.02
YHR124W −220 1.17 0.912 0.641 0.582 9.019 24.16 18.2 25.73
YGL138C −150 1 1.061 0.622 0.729 8.813 25.39 13.98 30.78
YLR341W −150 1 0.984 0.663 0.973 8.465 28.8 14.07 37.86
YGR059W −285 1.17 0.908 0.734 0.84 15.3 31.82 29.84 46.53
YGL015C −120 0.89 0.816 0.785 0.858 6.785 14.48 11.05 19.09
YNL128W −150 1.13 0.879 0.869 0.88 6.592 14.6 10.2 21.21
YOL132W −110 0.97 0.757 0.862 0.689 9.888 36.34 22.09 46.12
YPL021W −275 0.9492 0.832 1.03 0.906 6.802 16.65 14.25 25.78
(Continued)
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Table A1 | Continued
ORF Position PWM score t0 t0.5 t2 t5 t7 t9 t11.5
YNL204C −95 1 0.817 1.021 0.727 9.11 20.96 13.15 19.52
YPR078C −200 1 0.775 0.83 0.597 10.22 21.85 10.67 24.12
YOR190W −200 0.749736 0.807 0.643 0.77 4.394 20.05 17.58 28.51
YOR242C −220 0.603954 0.84 0.76 0.772 5.091 20.51 12.33 33.93
YBR285W −220 0.6786 1.259 2.197 0.955 1.311 4.261 4.408 3.632
YER100w −180 0.579852 0.91 0.959 0.91 0.907 2.473 2.403 1.679
YFL024C −370 0.9492 0.934 0.982 0.899 0.953 1.983 1.428 1.492
YKR019C −290 1 0.759 1.423 1.21 1.761 5.916 4.075 3.305
YDL103C −80 0.6786 1.106 1.13 2.457 3.24 6.293 7.124 7.375
YKL042W −130 0.8424 1.11 1.028 1.684 4.075 5.066 9.726 14.7
YDR516C −290 0.6786 0.825 0.833 0.375 1.762 7.44 7.489 18.86
YBR180W −140 0.7137 1.118 0.753 0.825 1.679 3.822 3.977 4.057
YGL162W −440 0.9492 1.079 0.615 0.629 2.384 8.46 9.129 7.724
YBL079W −210 0.89 0.867 0.93 0.868 1.044 1.61 1.47 1.505
YGL003C −940 0.497016 0.851 1.044 0.671 1.508 4.659 3.879 3.94
YFL040W −120 1 0.849 0.929 0.81 2.22 8.651 6.16 7.922
YDR281C −260 1.17 0.773 0.95 0.873 1.474 2.908 2.524 2.347
YKR031C −970 0.874692 0.972 1.195 0.969 1.776 3.156 2.685 2.777
YCL048W −100 1 1.037 0.882 0.849 2.105 5.175 6.924 8.885
YKL189W −270 0.9828 0.984 1.058 0.699 2.842 8.395 8.276 11.78
YOR339C −110 1.17 0.66 0.938 0.66 2.818 6.399 7.83 9.111
YER115c −270 0.8424 0.893 0.851 1.303 4.93 19.18 14.16 27.39
YGL230C −200 1 0.879 0.85 0.997 2.96 7.934 7.007 11.31
YOR214C −240 1.17 0.99 0.753 1.511 2.94 10.17 8.95 16.39
YCR054C −100 0.6903 0.862 0.599 0.708 1.085 2.989 1.94 2.469
YGR109C −390 0.9492 0.942 0.754 1.168 2.41 18.01 6.301 18.42
YIR013C −160 0.97 0.898 0.765 0.685 2.155 17.98 5.302 23.31
YNR034W −215 0.97 0.875 0.696 0.9 1.613 11.27 10.11 25.48
YDR147W −90 0.97 0.894 0.63 0.972 2.13 4.719 3.795 3.775
YER105c −160 1.17 0.782 0.701 0.903 1.376 2.355 1.998 1.96
YER123w −250 1.17 1.031 0.655 0.854 2.708 5.658 3.827 4.662
YOR297C −155 1.17 0.813 0.724 1.005 2.462 4.483 3.337 2.762
YDR273W −130 1 0.785 1.019 1.332 10.35 17.64 15.01 22.09
YBR148W −230 0.9828 0.81 1.058 1.273 12.24 31.58 12.95 18.16
YOL091W −110 1 0.716 0.863 1.268 23.86 35.63 20.94 18.92
YPL033C −80 0.59 0.702 1.038 1.443 12.08 20.52 11.89 13.9
YMR232W −70 0.6408 0.787 1.197 1.27 3.004 7.303 5.206 6.215
YIL104C −500 0.8136 0.855 0.608 0.76 0.955 1.918 1.934 1.641
YER168c 0 0.8424 1.125 0.63 0.741 1.138 1.995 1.826 1.803
YKL096W −250 1.13 1.001 0.27 0.235 1.449 7.336 5.276 5.502
YOR338W −160 1.13 0.979 0.263 0.399 2.107 3.99 2.855 2.927
YKL171W −200 0.749736 0.891 0.8 0.766 1.252 1.886 1.472 1.289
YNL121C −120 0.9828 0.811 0.584 0.521 1.238 2.91 2.066 1.642
YMR252C −165 1.17 0.737 0.779 2.045 1.544 2.281 3.069 2.112
YPL026C −5 0.8424 0.95 0.764 1.401 1.77 2.208 1.837 1.819
YMR001C −300 1.17 0.79 2.314 2.194 13.99 27.04 14.12 21.87
YDL239c −90 0.874692 0.754 2.022 3.434 10.08 27.01 19.85 16.47
YOR033C −955 0.749736 0.831 1.791 2.556 9.12 14.95 16.02 15.48
YJR036C −240 0.84 0.896 2.749 2.642 6.482 13.07 13.31 16.57
YIL144W −200 1 1.022 3.046 3.225 8.412 11.08 7.961 10.03
YMR198W −100 0.97 0.729 3.509 5.878 4.756 12.52 7.767 6.062
YOR177C −230 0.8424 0.828 3.658 3.208 5.039 8.42 7.585 5.789
(Continued)
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Table A1 | Continued
ORF Position PWM score t0 t0.5 t2 t5 t7 t9 t11.5
YKR034W −380 0.7137 0.879 7.614 7.731 2.533 3.392 2.375 3.831
YNL202W −190 1 0.914 3.068 2.073 1.493 2.572 2.466 3.039
YBR069C −140 1.13 1.186 0.897 0.221 0.563 1.621 2.166 2.715
YGL181W −100 0.72 1.371 1.425 0.699 0.834 1.294 1.77 1.45
YFL023W −280 0.9492 0.959 0.81 0.784 0.772 1.065 1.291 1.619
YNL217W −210 0.6984 0.806 0.513 0.382 0.612 1.861 1.923 1.555
YHR019C −190 0.5499 0.797 0.477 0.451 0.479 0.743 0.586 0.554
YAL034AW −200 0.749736 1.08 0.577 0.997 1.021 1.211 1.564 1.263
YDL207w −140 0.61 0.821 0.489 0.825 0.608 0.717 1.004 0.921
YIL091C −370 0.6893 0.999 0.452 0.503 0.613 0.632 0.966 0.822
YNL119W −660 1.0413 0.889 0.17 0.26 0.242 0.275 0.396 0.618
YML106W −30 0.8424 0.885 0.51 0.705 0.681 0.575 0.863 0.833
YNR053C −180 0.3948 0.905 0.084 0.318 0.55 0.351 0.588 0.584
YEL015w −360 1.13 0.906 0.689 0.939 0.834 0.866 0.668 0.682
YER122c −210 1.17 1 0.769 1.058 0.85 0.85 0.768 0.77
YMR011W −530 0.6554 0.862 0.177 0.861 0.961 0.488 0.511 0.551
YDL102W −300 1.17 1.035 1.04 1.39 1.179 1.238 1.187 1.164
YFL014W −400 0.97 1.343 0.75 3.633 2.061 2.062 1.69 3.541
YOR166C −250 0.5723 0.886 0.753 1.128 0.969 1.121 0.83 1.038
YDR055w −380 0.844788 0.794 0.447 0.251 0.211 0.139 0.194 0.143
YKL060C −200 0.58 1.189 0.283 0.561 0.189 0.14 0.106 0.187
YGR060W −380 0.97 1.049 0.901 1.429 1.065 0.855 0.695 0.579
YKL126W −780 0.6893 0.913 1.093 1.038 0.927 0.899 0.579 0.582
YIL160C −345 1.17 1.007 3.977 1.962 0.841 0.942 1.444 2.791
YLL023C −200 0.8424 1.063 0.964 0.863 0.486 0.385 0.512 1.007
YOL139C −80 0.599508 0.899 0.646 0.854 0.63 0.547 0.787 0.869
YIL107C −90 0.97 0.829 1.421 1.288 1.181 1.203 0.936 0.989
YJL149W −120 0.603954 0.725 1.567 1.167 1.711 1.648 1.026 0.785
YMR145C −220 0.8148 0.857 1.167 0.858 0.755 0.957 0.727 0.587
YJL099W −200 0.6786 0.646 0.785 0.698 1.12 1.625 1.585 0.865
YJR039W −310 0.84 0.956 1.121 1.058 1.224 1.311 1.657 1.057
YJR025C −140 0.89 0.667 1.008 0.792 0.886 1.578 1.115 0.722
YER125w −200 0.6786 0.87 1.34 1.696 1.753 1.459 1.823 1.388
YOR373W −200 0.5499 0.823 1.109 1.454 1.111 1.257 1.354 1.097
YER099c −330 0.579852 0.928 1.198 0.942 0.993 1.285 1.094 1.383
YNL317W −170 0.6903 0.921 1.129 0.812 0.869 1.21 1.05 1.279
YGL002W −190 0.6786 0.875 1.5 1.328 1.15 2.07 1.89 1.656
YER155c −30 1.17 0.819 0.988 0.745 0.964 1.255 1.273 1.267
YPR035W −80 0.3422 0.777 1.049 0.922 0.854 1.562 2.001 2.087
YIL155C −100 0.6667 0.534 0.622 0.662 0.617 0.962 0.693 0.842
YLL032C −180 0.724104 0.676 0.656 0.693 0.76 0.876 0.809 0.828
YOR161C −340 0.9492 0.719 1.248 1.138 1.599 2.601 2.162 2.214
YKR020W −150 0.84 0.758 0.784 0.893 0.61 1 0.816 0.772
Column 1: Known and predicted target genes of Ndt80 (Jolly et al., 2005).
Column 2: The approximate positions of the potential Ndt80 binding sites used in this analysis. Potential Ndt80 binding sites were identiﬁed using the YEASTRACT
database (Teixeira et al., 2006), which searched DNA from −1000 to −1 of the target genes for the sequence CRCAAA (Jolly et al., 2005). The position of the site
with the highest PWM score is listed.
Column 3: PWM scores (Jolly et al., 2005) of the potential Ndt80 binding sites. A 9-bp-long DNA centering around the CRCAAA core sequence (Jolly et al., 2005)
was used to compute a PWM score.
Columns 4–10: mRNA expression levels from 0, 0.5, 2, 5, 7, 9, 11.5 h after the initiation of sporulation (Chu et al., 1998). Expression was calculated as the ratio of red
signal divided by green signal, after background subtraction.
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Table A2 | Phosphorylation of Cdk1 substrates.
Peptides Cln Cln-sum P -score
YCR088W ABP1 165 PPVKKSFT#PSKSPAP -3.06 1.68 0.95 121.3 648 1.4
YCR088W ABP1 169 KSFTPSKS#PAPVSKK -3.06 0.63 0.95 121.3
YCR088W ABP1 181 SKKEPVKT#PSPAPAA -1.74 0.61 0.95 54.4
YCR088W ABP1 183 KEPVKTPS#PAPAAKI -1.32 0.63 0.95 309.8
YCR088W ABP1 313 KGFRNEKS#PAQLWAE -1.18 2.75 0.95 41.2
YLR131C ACE2 486 IPGSSNNT#PIKNSLP -3.51 1.76 2.72 40.2 471.6 2.5
YLR131C ACE2 501 QKHVFQHT#PVKAPPK -3.46 1.49 2.72 18.2
YLR131C ACE2 392 SPGGLSIS#PRINGNS -3.28 0.78 2.72 34.9
YLR131C ACE2 385 FRLFEKTS#PGGLSIS -3.20 0.63 2.72 22.8
YLR131C ACE2 303 SNTSINGS#PSRKYHR -2.64 0.90 2.72 9.2
YLR131C ACE2 428 FTPRTQLS#PIHKKRE -2.48 0.86 2.72 125.1
YLR131C ACE2 259 GSPVILKT#PAMQNGR -2.24 0.83 2.72 13.6
YLR131C ACE2 564 SPTLHSTS#PLPDEII -2.07 0.56 2.72 20.8
YLR131C ACE2 80 LDIPLVPS#PKTGDGS -1.27 0.77 2.72 34.7
YLR131C ACE2 253 NSNSKPGS#PVILKTP -1.06 0.78 2.72 152.1
YJR083C ACF4 49 SKSPRVTT#PLKPKRL -3.10 0.65 0.69 157.7 269.6 4
YJR083C ACF4 62 RLAIPISS#PQRSTTN -3.04 0.91 0.69 50
YJR083C ACF4 71 QRSTTNQS#PVSDHAS -1.38 1.00 0.69 61.9
YDR216W ADR1 188 ASSVKFQT#PTYGTPD -2.07 0.60 0.53 0 0 −10
YBR059C AKL1 504 DPTISEQS#PRLNTQS -2.86 0.60 1.40 95.2
YBR059C AKL1 801 EALLIELS#PLKEDAG -1.54 0.87 1.40 47.1
YJL122W ALB1 80TLQNASSS#PASITTR -1.67 0.56 0.43 7.4
YOL130W ALR1 143YVESNIHT#PPKDVGV -2.07 0.51 0.43 28.7
YOL130W ALR1 188 VRKSSLVS#PVLEIPH -1.45 0.61 0.43 33.3
YKR021W ALY1 573 VLSSPVLS#PNVQKMN -1.42 1.19 1.48 0
YJL084C ALY2 213 NGPSRNLS#PINLLKR -2.27 1.68 1.65 61.6 78.6 3.4
YJL084C ALY2 176 GLSSLNLS#PLGAPGN -1.56 0.81 1.65 17
YKL185W ASH1 253TRSSKFHS#PSKESFD -1.23 0.60 1.79 30.9 101.4 2.6
YKL185W ASH1 452 RPKAYTPS#PRSPNYH -1.00 1.19 1.79 23.5
YKL185W ASH1 450 PVRPKAYT#PSPRSPN -1.00 0.96 1.79 23.5
YKL185W ASH1 455 AYTPSPRS#PNYHRFA -1.00 0.88 1.79 23.5
YKL052C ASK1 250 NSNNIESS#PLKQGHH -2.34 1.21 0.43 9.1 9.1 0.8
YGR097W ASK10 808 GFRSKVNT#PAIDDYG -2.47 1.29 0.81 0
YDL088C ASM4 464 SSPIVANS#PNKRLDV -1.08 0.61 0.68 8.8 8.8 1.8
YMR068W AVO2 315 VKTPVGVS#PKKELVS -2.29 0.91 1.47 38.2
YBR068C BAP2 16 SSGKKETS#PDSISIR -1.11 0.60 0.43 283
YJL020C BBC1 103 KDLPEPIS#PETKKET -1.03 0.51 1.10 98.8
YJL095W BCK1 816 PKPPANTS#PQRTLST -2.73 0.83 1.95 18.8 139.7 −10
YJL095W BCK1 747 PKMVFKTS#PKLELNL -1.36 0.84 1.95 98.5
YJL095W BCK1 411 HYETNVSS#PLKQSSL -1.33 0.89 1.95 22.4
YER167W BCK2 418 SSMSNRYS#PIRVASP -1.08 1.18 0.83 8.6 8.6 3.6
YIL033C BCY1 89 RSSVMFKS#PFVNEDP -1.19 1.71 0.43 8.1 8.1 0.5
YER155C BEM2 1038 MLINNPAT#PNQKMRD -1.47 0.70 1.11 11.7
YPL115C BEM3 324 ENKALGFS#PASKEKL -2.66 1.25 2.84 9.3 45.9 3.8
YPL115C BEM3 254 VINNHLHS#PLKASTS -2.50 0.91 2.84 36.6
YOR198C BFR1 336 ADDLVLVT#PKKDDFV -1.42 0.65 0.43 141.2
YFL007W BLM10 11 NNDDDIKS#PIPITNK -3.50 1.28 0.43 0
YFL007W BLM10 29 QLKRFERS#PGRPSSS -1.95 0.76 0.43 28.8
YNL233W BNI4 410 LRKNHDDT#PVKIDHV -2.64 0.51 2.48 163.6 163.6 −10
YBL085W BOI1 540 FNRISMLS#PVKSSFD -4.26 0.88 2.67 28.3 40.2 1.4
YBL085W BOI1 405 PKPPSYPS#PVQPPQS -3.02 2.23 2.67 5.95
YBL085W BOI1 412 SPVQPPQS#PSFNNRY -3.02 1.21 2.67 5.95
(Continued)
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Table A2 | Continued
Peptides Cln Cln-sum P -score
YER114C BOI2 652 KKSSFMLS#PFRQQFT -4.07 1.68 2.79 32.3 163.4 −10
YER114C BOI2 450 PKPPSYPS#PAQPPKS -1.78 1.18 2.79 2.55
YER114C BOI2 457 SPAQPPKS#PLLNNTR -1.78 1.05 2.79 2.55
YER114C BOI2 519 QGGGKALS#PIPSPTR -1.07 0.73 2.79 63
YER114C BOI2 523 KALSPIPS#PTRNSVR -1.07 0.65 2.79 63
YHR036W BRL1 56 PHFPSSPS#PLRNTLD -2.12 1.89 1.39 6.4
YPR171W BSP1 296 QLKPTTLS#PTMKNKP -1.14 0.76 0.77 44.9 136.2 2.8
YPR171W BSP1 309 KPKPTPPS#PPAKRIP -1.10 0.63 0.77 67.9
YPR171W BSP1 39 KPAGEALS#PVRSHNS -1.08 0.63 0.77 6.1
YPR171W BSP1 79YNYEMTFS#PKKTHYS -1.07 0.94 0.77 17.3
YKL092C BUD2 1066 GNLGNRFS#PTKLSRI -2.17 0.65 0.43 80
YCL014W BUD3 1515 NAQKVQES#PSGPLIY -1.86 0.75 0.90 30.6 196.6 2
YCL014W BUD3 1440 PVEELPNT#PRSINVT -1.78 0.61 0.90 9.3
YCL014W BUD3 1549 KDEPIWVS#PSKIDFA -1.62 1.21 0.90 156.7
YJR092W BUD4 167 PLLSYPES#PIHRSSI -1.55 0.65 1.81 25.9 25.9 5.8
YLR319C BUD6 327 IDDVSKAS#PLAKTPL -1.17 0.61 0.66 71.2 71.2 2.1
YLR353W BUD8 413YEGHKTPS#PLTKMNK -3.22 0.80 0.49 18.2 36.4 0.7
YLR353W BUD8 411 SRYEGHKT#PSPLTKM -3.22 0.63 0.49 18.2
YDL099W BUG1 277 AARNTTAT#PIQFADF -1.06 0.92 0.43 0
YKL005C BYE1 177 DVFLDEES#PRKRKRS -1.36 0.93 1.39 15.7
YNL278W CAF120 556 FASSVNDS#PSDRAKS -2.42 0.79 2.23 32.6 65.3 5.3
YNL278W CAF120 510 SPSIKRKS#PPLVISE -2.02 0.88 2.23 4.6
YNL278W CAF120 518 PPLVISES#PHKVHTP -2.02 0.70 2.23 4.6
YNL278W CAF120 871 VQPANINS#PNKMYGA -1.24 0.61 2.23 0
YNL278W CAF120 577 NNDRKATT#PEKFERG -1.11 0.95 2.23 23.5
YNL161W CBK1 93 PALNYPAT#PPPHNNY -1.99 2.09 0.52 0
YNL161W CBK1 109 ASNQMINT#PPPSMGG -1.99 0.65 0.52 0
YFR028C CDC14 429 SSAVPQTS#PGQPRKG -1.42 3.07 1.45 0
YAL038W CDC19 407 VLSTSGTT#PRLVSKY -1.89 1.23 0.43 0
YLR314C CDC3 503 ELSINSAS#PNVNHSP -2.24 0.63 0.43 557.4
YLR314C CDC3 509 ASPNVNHS#PVPTKKK -1.67 1.25 0.43 195.5
YMR001C CDC5 70 KLSALCKT#PPSLIKT -2.83 2.04 0.43 185.2 185.2 3.2
YPR019W CDC54 69 IRAAIGSS#PLNFPSS -1.07 2.46 0.64 0 0 1.9
YJL194W CDC6 368 NSAQVPLT#PTTSPVK -2.53 0.65 1.34 4.25 8.5 −10
YJL194W CDC6 372 VPLTPTTS#PVKKSYP -2.53 0.65 1.34 4.25
YPL160W CDC60 142 EEEIKEET#PAEKDHE -1.52 0.63 0.43 142
YGL003C CDH1 227 SQFFDSMS#PVRPDSK -3.18 2.91 2.53 33.7 337 4.1
YBR038W CHS2 86YRDSAHNS#PVAPNRY -3.58 1.08 0.43 633.6 1106.2 4.7
YBR038W CHS2 60 VFQGLPAS#PSRAALR -2.61 1.08 0.43 26.4
YBR038W CHS2 133 PVDPYHLS#PQQQPSN -2.57 0.65 0.43 0
YBR038W CHS2 100YAANLQES#PKRAGEA -1.53 1.46 0.43 446.2
YNL298W CLA4 445 PRYAQNSS#PTAAHFQ -1.18 0.73 1.19 30.8
YNL225C CNM67 121 VPNFIHST#PRENSSK -1.16 0.65 0.43 31.8
YPR030W CSR2 963 EATSVSAS#PRSSVSY -1.07 1.02 0.85 22.1 22.1 4.7
YOR042W CUE5 364 AETTYIDT#PDTETKK -1.68 1.44 0.43 74.8
YIR023W DAL81 867 SQSSPNVT#PSHMSRH -1.47 0.94 1.28 13.2 13.2 3.7
YGR092W DBF2 53 AGINDSPS#PVKPSFF -1.70 2.66 0.81 10.8 32.5 3.2
YGR092W DBF2 51 RPAGINDS#PSPVKPS -1.70 1.08 0.81 10.8
YGR092W DBF2 83 PDMDVSNS#PKKLPPK -1.70 0.84 0.81 10.8
YDR052C DBF4 11 PTKMIIRS#PLKETDT -3.93 1.38 0.43 31.2 31.2 4.7
YHR164C DNA2 237 KFSDLPSS#PIKAPNV -1.57 0.65 0.73 8.8 8.8 5.2
YER088C DOT6 487 SSDADMLS#PTHSPQK -2.06 0.93 1.80 38.45
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YER088C DOT6 491 DMLSPTHS#PQKTLSK -2.00 0.95 1.80 38.45
YBL101C ECM21 1028 NLDKLLST#PSPVNRS -1.89 0.96 1.07 0 31.7 1.8
YBL101C ECM21 1030 DKLLSTPS#PVNRSHN -1.89 0.91 1.07 13.2
YBL101C ECM21 33 KGQPFQPS#PTKKLGS -1.58 0.65 1.07 18.5
YJL201W ECM25 422TPVALQNT#PVLKPKS -1.38 0.95 0.69 0 0 0.1
YJL201W ECM25 411 SPQRSVTS#PTYTPVA -1.38 0.75 0.69 0
YBL047C EDE1 238 VNQPNRTT#PLSANST -1.81 0.67 1.80 15.6 15.6 1.1
YNL230C ELA1 235 QAGGQSSS#PKKGPLS -1.03 0.61 0.43 0 0 −10
YMR219W ESC1 1145 DRSNIFSS#PIRVIGA -1.69 0.63 0.43 4 4 −10
YBR102C EXO84 31 AKQKTPPS#PAKPKQK -1.82 0.92 0.43 24.15 48.3 2.3
YBR102C EXO84 28 SSPAKQKT#PPSPAKP -1.82 0.61 0.43 24.15
YFR019W FAB1 183 MQNSYART#PDSDHDD -1.15 0.70 0.49 6.6
YJL157C FAR1 15 SFEKKIHT#PPSGDRD -2.05 1.35 1.03 9.5 38.6 2.8
YJL157C FAR1 8 MKT#PTRVSFE -1.38 1.20 1.03 29.1
YDR130C FIN1 74 VTPRRIMS#PECLKGY -3.11 1.08 0.88 22.5 33 3.7
YDR130C FIN1 36 VFVRLSMS#PLRTTSQ -2.23 1.19 0.88 10.5
YER032W FIR1 375 PDLEHMKS#PPSTGLN -2.40 0.77 1.05 7.8 23 3.8
YER032W FIR1 84 PNEISQDS#PLKIVFP -2.05 0.93 1.05 6.1
YER032W FIR1 225 NLYLTPES#PLNRYHL -1.52 1.02 1.05 0
YER032W FIR1 399 EPSEEPTS#PTRQVNP -1.46 0.60 1.05 9.1
YNL068C FKH2 708 GSANRARS#PLHSNSN -1.69 1.94 2.34 14.7 35.1 4.4
YNL068C FKH2 833 ETKDINSS#PLKNQGG -1.51 0.60 2.34 20.4
YPL221W FLC1 714 SPDRASSS#PNSKSYP -1.10 0.84 0.43 29.4
YAL035W FUN12 386 AKSTPAAT#PAATPTP -1.07 0.63 0.43 21.2
YAL034C FUN19 211 RLPSPLAS#PNLNRQA -2.52 0.65 1.38 0 0 −10
YAL034C FUN19 207 SSSSRLPS#PLASPNL -2.52 0.65 1.38 0
YOR178C GAC1 66 KSEIFCTS#PEKNVRF -1.70 0.64 1.49 63.8 63.8 2.5
YOL051W GAL11 163 QQQRRQLT#PQQQQLV -1.24 0.74 1.37 8.7
YPL248C GAL4 703 SPGSVGPS#PVPLKSG -1.02 0.65 0.62 11.9 11.9 −10
YDL226C GCS1 170 LENRRSAT#PANSSNG -4.40 1.11 0.43 6.4
YDL226C GCS1 161 VAQSREGT#PLENRRS -1.32 1.89 0.43 170.9
YMR255W GFD1 111 EISPPPVS#PSKMKTT -1.87 0.65 0.44 44
YMR255W GFD1 106 SQKATEIS#PPPVSPS -1.43 0.60 0.44 0
YDR309C GIC2 337 AFFPSRQS#PLPKRRN -3.37 0.79 0.85 17.2
YDR507C GIN4 462 IVNQSSPT#PASRNKR -3.48 0.65 0.43 16.5 44.1 3.9
YDR507C GIN4 435 ASSSNLTT#PGSSKRL -2.46 0.76 0.43 8.1
YDR507C GIN4 460 STIVNQSS#PTPASRN -1.74 0.87 0.43 19.5
YER054C GIP2 213 GVQARDGS#PMLIRSK -1.18 0.65 1.26 38.1
YAL031C GIP4 520 ETKKSVVS#PEKRKLI -1.00 0.65 0.69 44.9
YDR096W GIS1 696 ISREASKS#PISSFVN -2.86 0.60 0.99 29
YDR096W GIS1 425TTISRISS#PLLSRMM -1.43 0.73 0.99 9.2
YLR258W GSY2 655 RPLSVPGS#PRDLRSN -1.65 2.96 0.43 528.1
YMR192W GYL1 17 ERIEVPRT#PHQTQPE -2.35 0.76 0.57 18
YOR070C GYP1 546TPTKDFQS#PTTALSN -3.64 0.84 0.78 9.15 28 −10
YOR070C GYP1 539 PRVASFVT#PTKDFQS -3.64 0.84 0.78 9.15
YOR070C GYP1 555TTALSNMT#PNNAVED -2.71 0.60 0.78 9.7
YDL234C GYP7 265 DSWLTNNS#PIQKSQI -1.18 0.56 0.43 0
YJL165C HAL5 64 IITSNVSS#PSISPVH -1.58 0.80 0.46 0 0 1.4
YOR358W HAP5 8 MTDRNFS#PQQGQGP -1.03 0.72 0.43 7.8
YDL223C HBT1 671 KQDEDPLS#PRQTTNR -1.35 0.56 0.43 22.7
YDR458C HEH2 123 MQIQEEKS#PKKKRKK -1.53 1.97 1.70 156.1
YIL112W HOS4 690 KKREKTQS#PILASRR -3.73 0.65 1.48 29.6 43.7 3.4
(Continued)
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YIL112W HOS4 290 NLSNMNSS#PAQNPKR -2.89 0.79 1.48 14.1
YOL123W HRP1 462TSNTDSGS#PPLNLPN -1.02 0.91 0.43 0
YKL101W HSL1 1220 ILSKLRLS#PENPSNT -2.90 1.08 0.54 22.8 22.8 0.7
YHR094C HXT1 31 GRSKAMNT#PEGKNES -2.04 0.67 0.43 6 6 0.6
YJL146W IDS2 130 PEPSERAS#PIRQPSV -1.10 0.65 0.43 8.8
YHR132W-A IGO2 128 SSGPPPRS#PNK -2.83 1.27 0.43 566.3
YNL106C INP52 1016 EISIVSVS#PRKGESN -4.31 0.81 0.43 22.45 44.9 −10
YNL106C INP52 1005 EPSSKLLS#PTKEISI -4.31 0.59 0.43 22.45
YOR109W INP53 986 PSTSKEKS#PTPQTST -4.34 0.51 0.43 20.9
YOR109W INP53 988TSKEKSPT#PQTSTAS -2.25 1.46 0.43 0
YPL209C IPL1 76 MESSKIPS#PIRKATS -2.10 1.23 0.68 13 13 2.6
YPL242C IQG1 49 NSSLNIAS#PSHLKTK -5.16 1.10 0.88 52.8 154.4 −10
YPL242C IQG1 365 NKSLSYYS#PTISKYL -3.41 1.13 0.88 15.7
YPL242C IQG1 354 PTPSLEYS#PIKNKSL -2.71 0.82 0.88 49.5
YPL242C IQG1 315 NCSDFSNT#PSPYNEA -1.80 0.63 0.88 5.1
YPL242C IQG1 404 KYSPSHYS#PMRRERM -1.70 1.05 0.88 18.6
YPL242C IQG1 268 NINTAPAS#PEEPKEK -1.26 0.80 0.88 9.4
YPL242C IQG1 317 SDFSNTPS#PYNEAPK -1.14 0.67 0.88 3.3
YBR245C ISW1 694TSTGSAGT#PEPGSGE -2.32 1.11 0.43 20.3
YOR304W ISW2 1079TSATREDT#PLSQNES -3.00 0.74 0.43 43.8
YPR141C KAR3 21TQHLSTPS#PKNDILA -2.64 1.01 0.43 51.4 51.4 3.4
YPL269W KAR9 632TPLSQLLS#PREGRLD -1.11 0.93 0.92 4.5 4.5 0.8
YPL269W KAR9 496 NPFFDPES#PNKGKLI -1.11 0.75 0.92 0
YHR158C KEL1 613 ANQIKNNS#PILETLP -3.02 2.21 1.64 108.1 175.1 2.1
YHR158C KEL1 503 APLASAPS#PAPKDFS -2.93 0.89 1.64 11.2
YHR158C KEL1 67 SNVNKTSS#PPMFARK -1.60 1.18 1.64 55.8
YHR158C KEL1 689 GVAQMASS#PSKDQFK -1.16 0.87 1.64 0
YHR102W KIC1 735 PLFGVGTS#PNRKPAG -2.07 0.74 0.79 9.8 9.8 0.8
YLR096W KIN2 24TSKGGSLS#PTPEAFN -3.37 1.01 1.31 25.3 81.6 3.6
YLR096W KIN2 609 IPEQAHTS#PTSRKSS -1.59 1.02 1.31 22.8
YLR096W KIN2 643 EYQQRSAS#PVVGEHQ -1.09 0.86 1.31 33.5
YOR233W KIN4 460 GLVTIPGS#PTTARTR -2.37 0.77 1.32 38.1
YKL168C KKQ8 37 PPRSRDSS#PINVTRI -2.07 0.65 0.50 6.6 6.6 −10
YJR070C LIA1 281 EALGAIAS#PEVVDVL -1.28 0.75 0.43 0
YGL090W LIF1 261 KPISELNS#PGKRMKR -1.98 0.84 0.43 13.1 13.1 −10
YDR439W LRS4 146 KPTIHLLS#PIVNRDK -3.40 0.98 0.43 32.6 58.5 2.3
YDR439W LRS4 230 RLSALQKS#PELRKER -2.94 0.51 0.43 25.9
YAL024C LTE1 212YARQSFAS#PDFRNQS -4.00 0.91 2.06 33.6 41 4.6
YAL024C LTE1 614 SEAITNMT#PRRKNHS -2.33 0.81 2.06 7.4
YDL182W LYS20 396 NFHAEVST#PQVLSAK -1.25 1.22 0.43 119.8
YDL131W LYS21 410 DFHAELST#PLLKPVN -1.00 1.25 0.43 357.4
YJL013C MAD3 478 AVKPRQLT#PILEMRE -2.92 0.75 0.55 11.2 11.2 −10
YKL093W MBR1 69 FNFQPDSS#PCNAKCQ -2.59 0.65 0.43 8.9
YEL032W MCM3 781 QPASNSGS#PIKSTPR -1.90 0.75 0.43 42.6 42.6 3.1
YGL197W MDS3 1387 KSSAFPQS#PIRAYGS -2.90 0.84 1.03 15.8 32.4 −10
YGL197W MDS3 693 EDDEDPVS#PKPVSKS -1.08 0.65 1.03 16.6
YOR174W MED4 237 QMAKKEGT#PKTDSFI -1.09 0.63 0.43 18.5
YIL046W MET30 67 KMTMATRS#PSSSPDL -1.27 0.68 0.43 7.2
YGL035C MIG1 264 QQQQNSLS#PRYSNTV -2.20 0.88 2.24 21.2
YMR036C MIH1 27 FQKISLKS#PFGKKKN -4.30 0.83 2.16 29.1 29.1 3.9
YNL074C MLF3 297 PATSPYVS#PQQSARQ -2.97 1.18 1.07 12.8
YNL074C MLF3 79 KNSNNVSS#PLDNVIP -2.18 0.65 1.07 29.8
(Continued)
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YNL074C MLF3 56 FYNLQTIS#PIPISGS -1.94 0.65 1.07 5.7
YNL074C MLF3 265 CPFILKRS#PPQAYSS -1.77 0.56 1.07 37.4
YNL074C MLF3 183 SSESSPAS#PDLKLSR -1.68 0.65 1.07 5.7
YNL074C MLF3 180TLPSSESS#PASPDLK -1.60 0.65 1.07 9.8
YLL061W MMP1 21 FSTSVLST#PSNEGNN -3.83 0.63 0.43 0
YLR190W MMR1 37 SFQNLLNS#PTKLKLD -1.11 0.83 0.51 0 0 3.8
YIL106W MOB1 80 ESDHGRMS#PVLTTPK -4.65 0.65 0.44 79.5 143.6 3.8
YIL106W MOB1 36 ANNAGSVS#PTKATPH -1.20 1.07 0.44 64.1
YFL034C-B MOB2 76 SQQLTSTT#PQSQQQE -1.03 1.02 0.74 0
YPL082C MOT1 791 SFVSEIFS#PVMNKQL -2.30 0.65 0.43 7.3
YLR219W MSC3 46 ASAASAAS#PDRTNYS -1.13 0.65 0.63 9.6 9.6 2.1
YDR097C MSH6 228YNTSHSSS#PFTRNIS -1.84 1.18 0.43 33.1 33.1 5.3
YLR116W MSL5 378 SRYAPSPS#PPASHIS -1.21 1.06 0.71 126.6
YLR116W MSL5 376 ASSRYAPS#PSPPASH -1.21 0.74 0.71 126.6
YKL062W MSN4 178 FNENIELS#PHQHATS -1.58 0.79 1.42 2.2
YKL062W MSN4 161 EQLEKVFS#PMNPIND -1.58 0.65 1.42 2.2
YAR033W MST28 179TATSIGNS#PVTAKPE -1.19 0.51 0.43 9.1
YPL070W MUK1 245 IVGTSVSS#PNKMKTF -2.42 0.99 0.43 15
YPL070W MUK1 67 ERLENNKS#PILTKQE -1.10 0.73 0.43 32.3
YLR457C NBP1 253 LKIDLSPS#PIRRTNS -1.04 1.12 0.56 3.45 6.9 3.7
YLR457C NBP1 251 KPLKIDLS#PSPIRRT -1.04 0.94 0.56 3.45
YBL024W NCL1 426TEKLSSET#PALESEG -1.76 0.75 0.43 11.7
YJL076W NET1 676 RNILPQRT#PRSAAKR -4.43 0.84 1.05 354.8 478.8 4.6
YJL076W NET1 1056TQLMDMSS#PPSVKSK -3.50 1.12 1.05 12.65
YJL076W NET1 1042 VNKKINAT#PDKIPVT -3.50 1.02 1.05 12.65
YJL076W NET1 1032 SSKIEAPS#PSVNKKI -3.46 0.56 1.05 44.1
YJL076W NET1 252 PPPTQPQS#PPIRISS -2.69 1.10 1.05 9.5
YJL076W NET1 830 SFPVVGGS#PSVATKG -2.49 0.64 1.05 8.3
YJL076W NET1 447 SIADNNGS#PVKNSPL -2.23 1.18 1.05 9.3
YJL076W NET1 452 NGSPVKNS#PLGDAMP -2.23 0.91 1.05 9.3
YJL076W NET1 166 RSKLNNGS#PQSVQPQ -2.13 0.65 1.05 0
YJL076W NET1 297 QQRLLSGT#PIMSTMT -1.81 1.18 1.05 5.2
YOR056C NOB1 367 GNRYSVAS#PLSKNSQ -3.14 1.69 0.58 13
YPR072W NOT5 306 FDNSTLGT#PTTHVSM -1.33 0.97 0.55 38.1
YML059C NTE1 645 RNAQLSTS#PLSLDNT -1.12 0.66 0.44 0
YDR001C NTH1 66 MSVFDNVS#PFKKTGF -5.54 0.75 0.43 68.7 68.7 2.4
YOR098C NUP1 767 HNKEKSNS#PTSFFDG -1.13 0.89 1.29 11.8 11.8 5.2
YIL115C NUP159 854 HVKAKSES#PFSAFAT -1.72 1.83 2.37 19.5
YIL115C NUP159 735 FKFGTQAS#PFSSQLG -1.09 1.13 2.37 0
YAR002W NUP60 460 VQPDLSVT#PQKSSSK -4.10 0.79 1.02 25.2 239 2.1
YAR002W NUP60 222 FNYSSLPS#PYKTTVY -2.35 1.65 1.02 23
YAR002W NUP60 382 NVVVAETS#PEKKDGG -1.47 1.22 1.02 153.5
YAR002W NUP60 312 IRKHKRVS#PNAAPRQ -1.17 0.60 1.02 37.3
YHR195W NVJ1 298 SLLHIQVS#PTKSSNL -1.06 0.65 0.43 11.4
YHL029C OCA5 8 MHDKKS#PMANSHY -1.60 0.83 0.58 8.2
YBR060C ORC2 217 LTLSRNFT#PTPVPKN -1.30 0.87 1.08 8.8 8.8 3.6
YPR162C ORC4 9TISEARLS#PQVNLLP -1.51 0.56 0.55 0
YHR118C ORC6 116 KQFAWTPS#PKKNKRS -1.12 1.58 1.30 12.45 24.9 4.1
YHR118C ORC6 114 PMKQFAWT#PSPKKNK -1.12 1.18 1.30 12.45
YGR178C PBP1 193 ERKLEKWT#PEEGAEH -4.18 1.35 2.14 8.4
YGR178C PBP1 436TPSAKTVS#PTTQISA -1.95 0.92 2.14 36.6
YER149C PEA2 345 PVTWDPSS#PSSVGSP -1.42 1.27 0.60 16.1
(Continued)
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YML123C PHO84 579 NNDIESSS#PSQLQHE -1.53 0.65 0.43 45.9
YLR273C PIG1 645 FRDYFYKS#PSP -2.40 0.63 0.99 0 0 1
YBL051C PIN4 541 LLRNSQIS#PPNSQIP -1.25 1.31 0.89 15.8
YBL051C PIN4 466 SMQPTLTS#PKMNIHH -1.01 0.79 0.89 53.9
YIL122W POG1 168 INASELAS#PRGHRRY -2.48 0.93 0.43 42.5 42.5 3.3
YNL102W POL1 215 KYLEIESS#PLKLQSR -2.32 0.83 0.43 7.4 119.5 2.3
YNL102W POL1 313 PFVTAPGT#PIGIKGL -2.02 2.07 0.43 3
YNL102W POL1 305 SRSNPSTS#PFVTAPG -2.02 0.83 0.43 3
YNL102W POL1 170 LRENLNSS#PTSEFKS -1.28 0.77 0.43 106.1
YBL035C POL12 111 FGLSIPKT#PTLKKRK -3.50 2.60 0.65 16.7
YLR018C POM34 221YLFKGLET#PLKARQR -1.68 1.18 0.85 9.8
YLR018C POM34 273 NDNNSPHT#PVTRKGY -1.13 0.65 0.85 76.9
YIL114C POR2 103 GDVNAFLT#PQSIKNA -3.59 0.88 0.43 0
YML016C PPZ1 265 AYSTPLNS#PGLSKLT -1.83 1.21 0.65 4.85
YML016C PPZ1 261 DGNTAYST#PLNSPGL -1.59 1.39 0.65 4.85
YML016C PPZ1 142 MIQMEPKS#PILKTNN -1.54 2.41 0.65 4.3
YDR436W PPZ2 299 NVNGRGTS#PIPNLNI -2.54 1.18 0.74 16.6
YDR436W PPZ2 310 NLNIDKPS#PSASSAS -2.54 0.59 0.74 16.6
YMR137C PSO2 193 SFISNPSS#PAKTKRD -2.99 0.64 0.43 11.7 11.7 −10
YML017W PSP2 340TPLSKLDS#PALELQS -1.19 0.75 0.46 0
YBL046W PSY4 434TYRENISS#PLGKKSR -2.48 1.02 0.43 23.2
YBL046W PSY4 347 FTNMDLTT#PKKYKHT -1.83 1.02 0.43 5.3
YJR059W PTK2 784 NSLRSLGS#PSVSSSK -2.44 0.65 2.12 25 246.8 2.3
YJR059W PTK2 69 GSGSGGNS#PSSSAGA -1.92 0.96 2.12 10.5
YJR059W PTK2 727 LKSMLNST#PTTPTHN -1.25 0.86 2.12 45
YJR059W PTK2 730 MLNSTPTT#PTHNGPT -1.25 0.73 2.12 45
YJR059W PTK2 737TPTHNGPT#PLPAKAG -1.08 0.65 2.12 121.3
YER075C PTP3 272TATTPLSS#PQMNLKL -2.45 0.65 1.14 8.1
YGR253C PUP2 56 GVEKRATS#PLLESDS -3.33 1.35 0.43 49.2
YDR217C RAD9 26 AIKEALHS#PLADGDM -1.43 0.63 1.44 11.8 50.2 3.8
YDR217C RAD9 937 KSMTNVLS#PKKHTDD -1.21 0.63 1.44 8.6
YDR217C RAD9 56 STNIIEGS#PKANPNP -1.15 1.07 1.44 29.8
YJR033C RAV1 1211 PVQKLLKS#PTKDRAY -1.08 0.63 0.43 83.8 83.8 2.4
YLR248W RCK2 46 DVSQITSS#PKKSFQD -1.26 0.51 0.43 213.2
YDR195W REF2 245 DDKNSSPS#PTASTSS -1.67 0.61 0.43 37.5
YDR028C REG1 898 RIVNNTPS#PAEVGAS -1.47 0.74 1.73 0
YDR028C REG1 896 SFRIVNNT#PSPAEVG -1.47 0.63 1.73 0
YDR028C REG1 421 NLDQNLNS#PDNNRFP -1.10 0.60 1.73 6.6
YOR217W RFC1 48 DQESTNKT#PKKMPVS -2.12 0.56 0.43 0
YOR127W RGA1 278 SRNLLNKT#PLRNSSG -4.58 1.73 1.92 35.2 55.1 3.7
YOR127W RGA1 331 LLTSVLHS#PVSVNMK -3.28 1.27 1.92 14.3
YOR127W RGA1 291 SGQYLAKS#PSSYRQG -2.53 1.69 1.92 5.6
YDR379W RGA2 772 GKVPLSPS#PKRLDYT -2.84 0.77 1.92 26.6 123.4 2.3
YDR379W RGA2 763 RVHDELPS#PGKVPLS -2.84 0.65 1.92 26.6
YDR379W RGA2 770 SPGKVPLS#PSPKRLD -2.84 0.65 1.92 26.6
YDR379W RGA2 380 SKSMNHVS#PITRTDT -1.48 0.60 1.92 15.2
YDR379W RGA2 733 DLESQQRS#PNSSSGG -1.34 0.75 1.92 28.4
YDR137W RGP1 370 SSIIDIDS#PLEDNEF -1.31 0.56 0.83 26.2
YKL038W RGT1 229 SYNTVQQS#PITNKHT -2.04 1.16 0.96 0 5.3 −10
YKL038W RGT1 469 EASSPGST#PQRSTKK -1.85 1.05 0.96 5.3
YBR275C RIF1 45 KTNLPPPS#PQAHMHI -1.75 0.63 0.91 0 0 −10
YFL033C RIM15 1565 PTMTKFKS#PLSPANT -1.55 1.30 3.06 4.3 4.3 −10
(Continued)
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YPR018W RLF2 94 KLLCYKNS#PIQSTKY -2.47 0.83 0.54 46.4 53.9 2.2
YPR018W RLF2 515 QTASQSQS#PEKKQKA -1.54 1.52 0.54 7.5
YLR371W ROM2 171 DHPLPPMS#PRNEVYQ -1.97 0.79 0.43 10.5 18.6 −10
YLR371W ROM2 216 STGSASTT#PTQARKS -1.10 0.92 0.43 8.1
YER169W RPH1 575 SLIKRVKS#PNIVTLN -3.39 1.18 1.15 8.3
YER169W RPH1 561 ISHSAPHS#PVNPNIS -1.38 0.77 1.15 28.7
YER169W RPH1 430 SKSSGVSS#PLLSRMK -1.08 1.18 1.15 19
YDR418W RPL12B 38 KIGPLGLS#PKKVGED -2.25 2.73 0.43 411
YIL153W RRD1 341 IEQANAGS#PGREQTS -2.00 0.60 0.52 7.9 7.9 0.9
YLR357W RSC2 682 IPLSRVGS#PGAGGPL -2.69 1.09 0.94 81.6
YLR357W RSC2 243 LRDNRSTT#PSHSGTP -1.25 0.73 0.94 11.2
YOR014W RTS1 242 HSFERLPT#PTKLNPD -3.54 1.45 1.12 17.2 17.2 4.4
YDR159W SAC3 866 SDKNLIFS#PVNDEFN -2.76 0.74 0.87 10 100.4 −10
YDR159W SAC3 600 VKPQINTS#PKRVATR -1.27 0.66 0.87 90.4
YDR389W SAC7 46 ENITVPRS#PTSLSRN -1.92 0.65 2.11 13.4 121.6 2.1
YDR389W SAC7 16 GSKIENVS#PSKGHVP -1.49 0.80 2.11 108.2
YER129W SAK1 966 KLSELSNS#PQKGSNN -1.63 0.56 1.41 16.6 25.3 6.4
YER129W SAK1 36 SSSVSLRS#PTKSSAT -1.47 0.65 1.41 8.7
YER120W SCS2 204 EKQTSNST#PAPQNQI -1.76 0.56 0.43 11.6
YGL056C SDS23 405 SSSPSPST#PPVTTLP -1.32 0.60 0.92 0
YBR214W SDS24 458TAMEDPPS#PRSSAIA -1.30 0.86 0.86 466.8
YLR166C SEC10 485 NVDAFMHS#PRGNTHS -1.44 0.60 0.43 24.7
YPL085W SEC16 607 VSVPNIVS#PKPPVVK -2.34 0.76 2.62 12.8 191.6 1.6
YPL085W SEC16 1515 IGDSLQGS#PQRIHNT -1.43 0.65 2.62 178.8
YDL195W SEC31 836 PSQPSMAS#PFVNKTN -1.23 0.91 1.47 0
YDL195W SEC31 980 PSSVSMVS#PPPLHKN -1.07 1.23 1.47 15.1
YDR170C SEC7 1240 DVWGKKAT#PTELAQE -1.37 1.42 0.43 23.5
YOR057W SGT1 171 NSSHSPIS#PLKIETA -1.37 0.51 0.43 40.5
YBL058W SHP1 315 GQGQRLGS#PIPGESS -1.29 2.61 0.43 80.5
YBL058W SHP1 322 SPIPGESS#PAEVPKN -1.05 0.65 0.43 31.4
YDL225W SHS1 447 SSPKFLNS#PDLPERT -2.11 0.79 0.43 103.7
YOL004W SIN3 304 DDPIRVTT#PMGTTTV -1.62 2.72 0.58 74.4
YOL004W SIN3 316TTVNNNIS#PSGRGTT -1.62 0.56 0.58 74.4
YDR422C SIP1 200 SSATASPS#PTRSSSV -1.06 0.75 0.43 5.15
YDR422C SIP1 198 LESSATAS#PSPTRSS -1.06 0.65 0.43 5.15
YDL042C SIR2 23 NKVSNTVS#PTQDKDA -1.13 0.56 0.43 20.2
YLR442C SIR3 454 HSMNENPT#PEKGNAK -1.13 0.88 0.64 26.6
YDR227W SIR4 389 KRMEILKS#PHLSKSP -2.96 0.56 0.53 19.8 38.8 4.8
YDR227W SIR4 342TSKKIVPS#PKKVAID -2.04 0.51 0.53 19
YKR072C SIS2 47 GKDSIINS#PVSGRQS -1.70 0.63 1.15 7.3
YKR072C SIS2 56 VSGRQSIS#PTLSNAT -1.33 0.65 1.15 8.9
YDR409W SIZ1 139 SPSVIRQS#PTQRRKT -2.41 0.75 1.67 12
YDR409W SIZ1 132 PPTVQQQS#PSVIRQS -2.41 0.66 1.67 12
YHR149C SKG6 126 LPTMKDYS#PGINHLY -1.61 0.51 0.43 0
YHR149C SKG6 232 PDNFSNCT#PIRASSR -1.61 0.60 0.43 4.5
YNL167C SKO1 113 IISPPILT#PGGSKRL -1.81 1.65 1.31 2.6
YNL167C SKO1 108 QQRPTIIS#PPILTPG -1.81 1.35 1.31 2.6
YNL167C SKO1 94 HNDVKKDS#PSFLPGQ -1.43 0.91 1.31 2.7
YBL007C SLA1 437 IKKNFTKS#PSRSRSR -2.93 0.77 0.74 81.7
YNL243W SLA2 294 PARTPART#PTPTPPV -1.62 2.12 0.43 325 580.3 1.9
YNL243W SLA2 308 VVAEPAIS#PRPVSQR -1.62 0.70 0.43 85.1
(Continued)
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YNL243W SLA2 298 PARTPTPT#PPVVAEP -1.13 0.60 0.43 85.1
YNL243W SLA2 296 RTPARTPT#PTPPVVA -1.09 1.02 0.43 85.1
YGL113W SLD3 467 IINSVPSS#PALRRVD -4.42 1.04 0.80 0
YDR515W SLF1 42TSPWKSSS#PDSNTVI -1.10 0.63 0.43 57.7
YBR156C SLI15 268 KVRTVKES#PIAFKKK -3.00 0.81 1.22 16.9 29.3 −10
YBR156C SLI15 144 SIHDTNKS#PVEPLNS -1.04 0.65 1.22 12.4
YNL047C SLM2 649 FYIENVDS#PRKSNQL -2.33 0.79 0.51 7.4
YLR086W SMC4 128 RLELLQLS#PVKNSRV -2.92 1.53 0.43 49.9 78.1 4.1
YLR086W SMC4 113YSQSPPRS#PGRSPTR -1.98 2.01 0.43 14.1
YLR086W SMC4 117 PPRSPGRS#PTRRLEL -1.98 1.40 0.43 14.1
YDR006C SOK1 193 NINNPSPS#PPPSSKQ -1.24 0.65 0.43 6.85
YDR006C SOK1 191YTNINNPS#PSPPPSS -1.24 0.64 0.43 6.85
YLL021W SPA2 1087 SPELAKNS#PLAPIKK -5.19 0.60 1.29 53.8 1190 3.4
YLL021W SPA2 585 NDVEEEES#PVKPLKI -3.34 1.18 1.29 453.7
YLL021W SPA2 646 EDNDKYVS#PIKAVTS -2.55 0.72 1.29 16.9
YLL021W SPA2 961TAQESIKS#PEAARKL -2.54 0.51 1.29 96.2
YLL021W SPA2 274 KGPEQLKS#PEVQRAE -2.09 0.65 1.29 71.3
YLL021W SPA2 599 ITQKAINS#PIIRPSS -2.04 0.84 1.29 19.2
YLL021W SPA2 254 NYWDVNDS#PIIKVDK -1.68 0.65 1.29 18.7
YLL021W SPA2 937 EADSRVES#PGMKEQI -1.58 0.65 1.29 91.4
YLL021W SPA2 979 GEVDKIES#PRMVRES -1.58 0.76 1.29 322
YLL021W SPA2 1080 EPNSQIVS#PELAKNS -1.57 0.91 1.29 7.5
YLL021W SPA2 883 EPLGNVES#PDMTQKV -1.44 0.60 1.29 32.7
YLL021W SPA2 910 ESDSRVES#PGMTGQI -1.33 0.56 1.29 6.6
YGL093W SPC105 356 DYAASVTT#PVKEAKD -1.10 0.79 1.43 13.9 13.9 −10
YPL124W SPC29 59 RAQERMSS#PLHRLSP -1.54 0.59 0.43 104 104 1.6
YKL042W SPC42 357 NMSETFAT#PTPNNR -1.23 1.18 0.90 18.6 18.6 0.5
YHR152W SPO12 118 QLQQRFAS#PTDRLVS -5.07 0.93 0.43 29.75 59.5 −10
YHR152W SPO12 125 SPTDRLVS#PCSLKLN -5.07 0.93 0.43 29.75
YER161C SPT2 173 KRPQKKAS#PGATLRG -1.18 0.77 0.43 0 0 −10
YML034W SRC1 241 LGKLSVKT#PIKNTNR -3.53 1.27 1.61 188.1 188.1 2.9
YML034W SRC1 80 KMDRPSSS#PSIASPR -3.03 0.51 1.61 96.1
YML034W SRC1 85 SSSPSIAS#PRRSRRA -2.60 0.51 1.61 81.7
YML034W SRC1 291 ANGTGHST#PLSKLKV -2.19 0.67 1.61 30.1
YKR091W SRL3 212 RVDNVNVS#PLRWSSH -2.87 0.80 0.83 10.8 10.8 2.3
YCL037C SRO9 40 PAPLPTSS#PWKLAPT -2.84 1.10 0.52 10.5
YDR293C SSD1 286 QQPQQQLS#PFRHRGS -2.67 1.17 0.43 0 57.5 0.1
YDR293C SSD1 267 KTRNNEYS#PGINSNW -2.52 0.75 0.43 12.6
YDR293C SSD1 231 RRATSNLS#PPSFKFP -1.30 1.12 0.43 23.8
YDR293C SSD1 492 NDSDSLSS#PTKSGVR -1.03 0.84 0.43 21.1
YLR006C SSK1 195 LLRFASVS#PYPKFHS -2.85 0.63 2.57 0 26.4 2.8
YLR006C SSK1 673TDSVLVKS#PQKPIAP -1.43 0.83 2.57 26.4
YNR031C SSK2 54TQARVASS#PISPGLH -2.48 0.91 0.51 45.3
YNR031C SSK2 57 RVASSPIS#PGLHSTQ -2.48 0.79 0.51 45.3
YDR443C SSN2 748 NDIPQTES#PLKTVDS -4.10 1.01 1.07 0 0 −10
YNL309W STB1 72 KTLLEAIS#PAKKPLH -5.02 1.13 1.13 47.9 174.9 2.9
YNL309W STB1 89TNKMTVIS#PVKFVEK -3.35 0.79 1.13 15
YNL309W STB1 99 KFVEKPNT#PPSSRQR -2.71 1.03 1.13 112
YFL026W STE2 382 NQFYQLPT#PTSSKNT -1.15 0.92 0.43 17.1
YHL007C STE20 203 STDIRRAT#PVSTPVI -2.47 0.60 1.11 33 160 −10
YHL007C STE20 562TPQQVAQS#PKAPAQE -2.28 0.90 1.11 7.1
YHL007C STE20 502 MNSAANVS#PLKQTHA -1.85 0.65 1.11 27.6
(Continued)
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YHL007C STE20 512 KQTHAPTT#PNRTSPN -1.53 0.65 1.11 13.2
YHL007C STE20 517 PTTPNRTS#PNRSSIS -1.11 0.60 1.11 79.1
YDR103W STE5 329 SNYTFLHS#PLGHRRI -2.83 0.65 0.96 28.4
YGR008C STF2 28 HTGNYGES#PNHIKKQ -1.50 1.04 0.43 195.4
YDL048C STP4 191TTGFKTIT#PSPPTQH -1.40 0.73 1.17 12.35
YDL048C STP4 193 GFKTITPS#PPTQHQS -1.40 0.73 1.17 12.35
YDR310C SUM1 738 QTENTSIS#PKKRRTE -1.71 0.51 0.53 34.1
YDR310C SUM1 379 KFHQIPSS#PSNPVSQ -1.19 0.65 0.53 0
YJL187C SWE1 373 DTDEEIST#PTRRKSI -2.17 1.04 2.89 6.6 15.4 4.6
YJL187C SWE1 111 DSRIKRWS#PFHENES -1.58 0.93 2.89 8.8
YER111C SWI4 806 PSKILENS#PILYRRR -3.48 0.77 1.12 0 13.7 1.9
YER111C SWI4 20 NTNHQNIT#PISKSVL -3.22 0.65 1.12 13.7
YDR146C SWI5 522 INTYTTNS#PSKITRK -4.00 1.38 2.61 0 365.8 4.7
YDR146C SWI5 492 FVISETPS#PVLKSQS -2.48 1.08 2.61 30.6
YDR146C SWI5 300 GFNDSLIS#PKKIRSN -2.41 0.80 2.61 7.8
YDR146C SWI5 261 SNTSFTGS#PSRRNNR -2.14 1.50 2.61 0
YDR146C SWI5 250 NSLSPMIS#PPMSNTS -2.14 0.71 2.61 0
YDR146C SWI5 664 GTSSVSSS#PIKENIN -2.08 1.15 2.61 142.1
YDR146C SWI5 505 QSKYEGRS#PQFGTHI -1.70 1.11 2.61 180.9
YDR146C SWI5 702 NGTGIMVS#PMKTNQR -1.57 0.74 2.61 4.4
YPR095C SYT1 297 AKNKPPLS#PSSFIRT -1.11 0.51 1.45 8.5
YMR005WTAF4 36TKPAFNLS#PGKASEL -1.68 0.95 0.43 22.7 22.7 2.4
YMR005WTAF4 49 ELSHSLPS#PSQIKST -1.17 1.35 0.43 0
YML072CTCB3 1373YAPVQSAS#PVVKPTD -1.81 0.67 0.43 0
YML072CTCB3 1350 NLNSTSVT#PRASLDY -1.57 1.04 0.43 158.9
YPL180WTCO89 546 KNSAAPAS#PLSNEHI -1.86 0.65 0.43 0
YML064CTEM1 240 SPSSKAPS#PGVNT -1.69 0.65 0.43 16.6
YKR062WTFA2 97 DDEDFGSS#PSKKVRP -2.23 0.84 0.43 15.4
YKL140WTGL1 466 RTHSADRS#PLSVQAD -1.88 0.65 0.43 26.5
YKR089CTGL4 756 SFSFSVAS#PTSRMLR -2.83 0.76 0.43 10.5
YKR089CTGL4 675 NSTLLTRT#PTKGDNH -1.98 0.65 0.43 73.8
YGL049CTIF4632 196TPFEKEAT#PVLPANE -4.68 1.09 1.91 0
YGL049CTIF4632 301 KSGASVKT#PQHVTGS -1.49 0.51 1.91 19.7
YNL088WTOP2 1250TKIKKEKT#PSVSETK -2.52 0.93 0.43 32.4
YLR183CTOS4 98 KFSSKLSS#PSRHTRV -2.08 0.77 2.85 8 8 4.9
YMR261CTPS3 148 APSARVCS#PSQEASA -1.53 0.61 0.52 748.4
YER093CTSC11 28TNTTPLLT#PRHSRDN -2.53 0.63 0.43 22
YML100WTSL1 77 ISRSATRS#PSAFNRA -2.52 0.60 0.52 20.6
YML100WTSL1 161 DSGSRIAS#PIQQQQQ -1.28 0.60 0.52 26.9
YML100WTSL1 147 IPTDRIAS#PIQHEHD -1.26 0.60 0.52 1323.2
YML100WTSL1 135 GSVERFFS#PSSNIPT -1.07 0.60 0.52 0
YOR124C UBP2 917 EDTTGLTS#PTRVAKI -1.18 0.63 0.43 3.3 3.3 0.4
YGR184C UBR1 300 PSNSPEAS#PSLAKID -1.13 0.56 0.43 3.4
YGR184C UBR1 296 AKTSPSNS#PEASPSL -1.13 0.56 0.43 3.4
YPL020C ULP1 25 NPYSPLFS#PISTYRC -1.62 0.97 1.00 0
YPL020C ULP1 21YHKKNPYS#PLFSPIS -1.62 0.88 1.00 0
YIL031W ULP2 984 IDDVAFSS#PTRGIPR -2.50 0.60 1.67 11.9 16.8 2.2
YIL031W ULP2 795 SPETASVS#PPIRHNI -1.03 0.65 1.67 2.45
YIL031W ULP2 788 EDPVRAAS#PETASVS -1.03 0.51 1.67 2.45
YML029W USA1 376 PPDTRSQS#PVSFAPT -1.40 0.77 0.43 10.1
YIL135C VHS2 301TGAALSRS#PSNQQYL -1.47 1.04 1.11 24.1
YOR054C VHS3 225 RSRSNSTS#PRPSVVV -1.48 1.20 1.13 28.3
(Continued)
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YLR410WVIP1 1107 FTPVNITS#PNLSFQK -2.33 1.58 0.89 30.4
YLL040C VPS13 1379 SESERTAT#PQSLQGS -1.32 0.63 0.43 0 0 −10
YLR337C VRP1 703 ISKNPTKS#PPPPPSP -1.24 0.51 0.98 44.9
YLR337C VRP1 709 KSPPPPPS#PSTMDTG -1.17 0.51 0.98 6.5
YML076CWAR1 126 KRKPRSRS#PTPFESP -1.03 0.60 0.68 29.5
YOR083WWHI5 154 RRSEVFLS#PSPRLRS -6.54 1.18 1.11 68.45 256.4 2
YOR083WWHI5 156 SEVFLSPS#PRLRSPP -6.54 1.11 1.11 68.45
YOR083WWHI5 88 SLQGIFMS#PVNKRRV -2.95 0.99 1.11 11.4
YOR083WWHI5 161 SPSPRLRS#PPTAARR -2.75 1.18 1.11 102.5
YOR083WWHI5 62 FGTPSPPS#PPGITKS -1.97 1.12 1.11 2.8
YOR083WWHI5 57 RLKNGFGT#PSPPSPP -1.97 1.04 1.11 0
YOR083WWHI5 59 KNGFGTPS#PPSPPGI -1.97 0.65 1.11 2.8
YHL028WWSC4 541 RTSTFLHS#PIQKQHE -2.25 0.60 1.18 10.6 10.6 −10
YDR369C XRS2 349 RAPEVEAS#PVVSKKR -2.34 0.65 0.43 0 0 −10
YBL005W-AYBL005W-A 409 NVSTFNNS#PGPDNDL -1.03 0.51 0.53 33.1
YCL019WYCL019W 1014TVESDTTS#PRHSSTF -1.68 0.51 0.49 31.6 31.6 −10
YDL089WYDL089W 441 NRPSKSLS#PLRKTPL -3.67 1.09 1.07 38.2 145.1 2.7
YDL089WYDL089W 446 SLSPLRKT#PLSARQK -3.67 1.05 1.07 38.2
YDL089WYDL089W 474 DINSILRS#PKKKKNY -2.40 1.32 1.07 68.7
YDL156WYDL156W 99 NQLLKMGS#PDGQDKN -1.13 0.64 0.43 5.3
YDL173WYDL173W 148 SLHATTSS#PNNNAPI -2.33 0.65 0.52 27.1
YDL173WYDL173W 246 GGAGNIIS#PKSSRNT -1.67 1.05 0.52 65
YDR089WYDR089W 238 NNSSLPAS#PRSIPLL -1.29 0.95 0.43 11.5
YDR239CYDR239C 63 APDIPPRS#PNRNAHS -2.10 0.65 0.63 17.5
YDR348CYDR348C 121 SATDFRRS#PPPVSRN -1.35 0.85 0.64 23.9 23.9 3.5
YEL043WYEL043W 847 RRSFHASS#PPFNSIW -1.12 0.91 0.54 6.1
YEL043WYEL043W 862 NSNTNQLS#PPLEEQY -1.12 0.51 0.54 6.1
YER079WYER079W 41 DLDQRSMS#PSNIASG -1.41 0.65 0.43 9.9
YFL042CYFL042C 149 ATIAEIGS#PLQQVEK -2.44 0.75 0.80 0 151 1.5
YFL042CYFL042C 103 SFKSNVPS#PVSRSTT -1.21 0.65 0.80 31.7
YFL042CYFL042C 110 SPVSRSTT#PTSPVSQ -1.01 0.65 0.80 119.3
YGR125WYGR125W 42 RASVSAMS#PPLCRSY -1.11 0.65 0.43 7.2
YGR237CYGR237C 117 PSKSYLRS#PSVERSR -3.13 0.61 0.47 29
YHR159WYHR159W 236 HLDPSLNT#PVKNRAF -3.11 0.80 0.81 203.8 259.1 3.4
YHR159WYHR159W 244 PVKNRAFS#PVYQNIP -2.72 0.80 0.81 14.8
YHR159WYHR159W 29 RNSIISMS#PVRKTGR -2.38 0.77 0.81 28.3
YHR159WYHR159W 286TNQSRSVS#PQDIQER -1.02 0.80 0.81 12.2
YIL024CYIL024C 107 QLMDIPLS#PHTRSNT -1.99 0.65 0.43 13
YIR007WYIR007W 594YHDTRAKT#PTPEPSP -1.38 0.97 0.43 10.85
YIR007WYIR007W 596 DTRAKTPT#PEPSPAS -1.14 0.61 0.43 10.85
YJL193WYJL193W 247 SGFSRQES#PLPLYEK -3.69 1.01 0.72 19.1
YKL105CYKL105C 980 SWTFGLPS#PLKRRTS -3.65 0.65 0.62 18.5 18.5 −10
YKR077WYKR077W 147 QPAATAPS#PLVSNII -2.19 0.65 0.58 0 0 −10
YKR077WYKR077W 157 VSNIIKPS#PKKLASP -2.19 0.65 0.58 0
YLL032CYLL032C 762 NTSQSGAS#PQRHKMP -1.87 0.51 0.58 16.1 16.1 1
YLR049CYLR049C 80 QGSPVAPS#PNHRSTM -1.24 0.59 0.43 0
YMR086WYMR086W 675 HSAIPLGT#PEKGKPK -3.94 0.77 0.78 364.4 379 −10
YMR086WYMR086W 870 QKENNVVS#PGVSSPN -1.91 0.56 0.78 5.6
YMR086WYMR086W 658 SIRSNSPS#PPEKINN -1.62 0.79 0.78 9
YMR124WYMR124W 586 FSSTFSDS#PSKQRII -1.71 0.94 0.83 16.9 16.9 −10
YMR196WYMR196W 1081 IDPMDPMS#PLNKDVS -1.25 0.60 0.43 4.4
YMR233WYMR233W 113 RKKKKNDS#PDSNSIS -3.86 0.60 0.43 21.4 21.4 −0.2
(Continued)
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YMR291WYMR291W 538 NEVDLLLT#PRTASMS -1.31 0.65 0.43 0
YNL058CYNL058C 292 SATSNTSS#PKKAHKR -1.63 0.90 0.62 68.6 68.6 2.3
YNL224CYNL224C 345 NNLLPSPS#PQLTEDI -2.60 0.79 0.43 10
YNL224CYNL224C 343 ADNNLLPS#PSPQLTE -2.60 0.65 0.43 0
YNL321WYNL321W 118 VPDLNTAT#PSSPKRM -1.97 0.83 0.43 5.9 11.8 3.7
YNL321WYNL321W 121 LNTATPSS#PKRMHSS -1.97 0.65 0.43 5.9
YNR047WYNR047W 201 GRRRSPST#PIMPSQN -2.09 1.35 1.32 3.15 48 3.6
YNR047WYNR047W 198TGTGRRRS#PSTPIMP -2.09 1.09 1.32 3.15
YNR047WYNR047W 175 REHSNCGS#PIMLSSS -1.56 0.65 1.32 0
YNR047WYNR047W 339 LKDTLNGS#PSRGSSK -1.48 1.08 1.32 10.2
YNR047WYNR047W 137 MTSVANAS#PASPPLS -1.38 0.84 1.32 10.5
YNR047WYNR047W 140 VANASPAS#PPLSPTI -1.00 1.33 1.32 10.5
YNR047WYNR047W 144 SPASPPLS#PTIPETD -1.00 1.09 1.32 10.5
YOL070CYOL070C 403YEDIIEET#PKKTKLK -1.14 0.65 0.61 7.2 7.2 3.1
YOR227WYOR227W 61 VPTKTIAS#PQRPLSG -1.02 0.68 0.72 60.1
YML027WYOX1 324 NPQKKTLT#PVKTSPN -1.42 1.35 2.07 0 0 2.8
YPL141CYPL141C 441 LSHEQSLS#PVQNIRQ -1.44 0.56 1.55 0 0 −0.9
YPL150WYPL150W 456YSHSIAGS#PRKSNNF -1.09 0.65 0.71 109.6
YPR091CYPR091C 676 SQPLNTLS#PKLEGRK -1.13 0.73 1.35 62.8
YPR115WYPR115W 969 ARRGSDLS#PFEMESP -3.18 0.51 0.80 17.9
YPR115WYPR115W 975 LSPFEMES#PLFEENR -2.70 0.65 0.80 5.5
YPR174CYPR174C 170 VNPLVTSS#PIHMSPL -2.85 1.12 0.49 17.6 35.2 2.5
YPR174CYPR174C 175TSSPIHMS#PLQSRQR -2.85 0.65 0.49 17.6
YIL063CYRB2 31 PIDKLDGT#PKRPREK -1.24 0.56 0.72 54.4
YHR016CYSC84 311 EDYDYGRS#PNRNSSR -2.60 0.63 0.43 7.1
YDR326CYSP2 572 FLNRRSFS#PSNLGNK -1.20 1.08 0.74 52.4
YNR039C ZRG17 58 QNRTFFAS#PRPSSLF -2.51 1.23 0.76 10.8
YER033C ZRG8 914 LNRRTLKS#PLRGGSK -4.46 1.20 1.19 32.4 32.4 −10
Column 1: Cdk1-phosphorylated peptides, according to Holt et al. (2009).
Column 2: Average S/N ratios of the phosphopeptides from cells arrested by the overexpression of a stable, mitotic cyclin (Holt et al., 2009). If a phosphopeptide was
not detected in this cell population, its ratio is entered as 0 here.
Column 3: Sums of the S/N ratios for every protein. These values are not corrected for Cdk1-dependent phosphorylation (Holt et al., 2009), but such a correction did
not alter our conclusion (not shown).
Column 4: P-scores of the proteins determined by Ubersax et al. (2003). If a protein was tested and found not to be phosphorylated, its P-score is entered as −10.
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